No Picture
News

Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

SAN DIEGO, Oct. 17, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present pre-clinical data and initial clinical data on MRTX849, a novel and optimized KRAS G12C i… […]

No Picture
News

DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time

SAN DIEGO, Oct. 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced that Mr. Saiid Zarrabian, Chief Executive Off… […]

No Picture
News

AFYX Therapeutics Presents Results from Rivelin Clinical Proof of Concept Study in Patients with Vulvar Lichen Sclerosus at the 2019 European Academy of Dermatology and Venereology Congress

SAN DIEGO and COPENHAGEN, Denmark, Oct. 9, 2019 /PRNewswire/ — AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results from a Phase 1 clinical proof of concep… […]

No Picture
News

Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC)

– Significant tumor regression observed with onvansertib in combination with standard-of-care paclitaxel in models of p53-mutated TNBC- Onvansertib preclinical data provides rationale for clinical trial targeting the 80% of TNBC that harbors the p53 mu… […]